(19)
(11) EP 1 683 520 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
18.11.2009 Bulletin 2009/47

(43) Date of publication A2:
26.07.2006 Bulletin 2006/30

(21) Application number: 05028731.7

(22) Date of filing: 11.03.1997
(51) International Patent Classification (IPC): 
A61K 31/335(2006.01)
A01N 43/02(2006.01)
A61K 51/04(2006.01)
A61P 35/00(2006.01)
 A61M 36/00(2006.01)
C07D 305/00(2006.01)
A61K 47/48(2006.01)
(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV RO SI

(30) Priority: 12.03.1996 US 13184

(62) Application number of the earlier application in accordance with Art. 76 EPC:
97917512.2 / 0932399

(71) Applicant: PG-TXL Company, L.P.
Houston, TX 77005 (US)

(72) Inventors:
  • Li, Chun
    Missoury city, TX 77459 (US)
  • Wallace, Sydney
    Houston, TX 77005 (US)
  • Yu, Dong-Fang
    Houston, TX 77062 (US)
  • Yang, David J.
    Sugar Land, TX 77478 (US)

(74) Representative: Bublak, Wolfgang 
Bardehle, Pagenberg, Dost, Altenburg, Geissler Galileiplatz 1
81679 München
81679 München (DE)

   


(54) Water-soluble paclitaxel produgs


(57) Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble chelator, polyethylene glycol or polymer such as poly (1-glutamic acid) or poly (1-aspartic acid). Also disclosed are methods of using the compositions for treatment of tumors, autoimmune disorders such as rheumatoid arthritis and for prediction of paclitaxel uptake by tumors and radiolabeled DTPA-paclitaxel tumor imaging. Other embodiments include the coating of implantable stents for prevention of restenosis.










Search report